ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

Our Pipeline

Our portfolio consists of four product candidates which target validated growth pathways applied to new patient segments and novel cancer metabolic pathways.

Programs
Discovery
Preclinical
Phase 1
Phase 2
Pivotal
Key Milestones

Global Rights

Varlitinib(ASLAN001)Pan-HER inhibitor
Biliary tract cancer (2nd line)

Completion of enrolment January 2019

Topline data 2H 2019

Biliary tract cancer (1st line)

Phase 1b data January 2019
ASLAN003DHODH inhibitor
AML

Dose optimisation 1Q 2019
ASLAN004IL-4/IL-13 Receptor inhibitor
Atopic dermatitis

SAD completion 1H 2019

Asthma

Partnered Programs

ASLAN002RON/MET inhibitor
Solid tumors


Varlitinib

Pivotal

Potential to be the first targeted therapy approved for biliary tract cancer

Read more about Varlitinib

ASLAN002

Phase 2

RON and MET inhibitor in Phase 2 development for solid tumours

Read more about ASLAN002

ASLAN003

Phase 2

Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

Read more about ASLAN003

ASLAN004

Phase 1

IL-4R / IL-13R inhibitor with the potential to be best-in-class therapy for atopic dermatitis and asthma

Read more about ASLAN004

Therapeutic Areas

We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.

Breast Cancer

Breast Cancer

The prevalence of breast cancer in Asia was approximately 2.3 million patients in 2012, while the prevalence in the United States was approximately 1 million, of which approximately 5% was metastatic in both cases [1].

Metastatic breast cancer has a five-year survival rate of 26% [2]. Approximately 20% of these patients have tumours with HER2 amplification and will typically receive the anti-HER2 monoclonal antibody therapies Herceptin and pertuzumab in first-line treatment and then ado-trastuzumab emtansine in second-line treatment [3]. In third-line treatment, patients receive the HER1/HER2 small molecule inhibitor lapatinib plus capecitabine.

[1] Globocan 2012. http://globocan.iarc.fr [2] ASCO Cancer.Net [3] Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guidelines Update. Journal of Clinical Oncology; 31: 3297-4013. DOI: 10.1200/JCO.2013.50.9984